134 related articles for article (PubMed ID: 7742678)
1. Strategies for reducing coronary risk factors in primary care: which is most cost effective?
Field K; Thorogood M; Silagy C; Normand C; O'Neill C; Muir J
BMJ; 1995 Apr; 310(6987):1109-12. PubMed ID: 7742678
[TBL] [Abstract][Full Text] [Related]
2. Cost effectiveness of lowering cholesterol concentration with statins in patients with and without pre-existing coronary heart disease: life table method applied to health authority population.
Pharoah PD; Hollingworth W
BMJ; 1996 Jun; 312(7044):1443-8. PubMed ID: 8664620
[TBL] [Abstract][Full Text] [Related]
3. Costs and cost effectiveness of cardiovascular screening and intervention: the British family heart study.
Wonderling D; McDermott C; Buxton M; Kinmonth AL; Pyke S; Thompson S; Wood D
BMJ; 1996 May; 312(7041):1269-73. PubMed ID: 8634617
[TBL] [Abstract][Full Text] [Related]
4. What can be concluded from the Oxcheck and British family heart studies: commentary on cost effectiveness analyses.
Wonderling D; Langham S; Buxton M; Normand C; McDermott C
BMJ; 1996 May; 312(7041):1274-8. PubMed ID: 8634618
[TBL] [Abstract][Full Text] [Related]
5. Cost effectiveness of incremental programmes for lowering serum cholesterol concentration: is individual intervention worth while?
Kristiansen IS; Eggen AE; Thelle DS
BMJ; 1991 May; 302(6785):1119-22. PubMed ID: 1904286
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of treatments to reduce cholesterol levels, blood pressure and smoking for the prevention of coronary heart disease: evaluative study carried out in Spain.
Plans-Rubió P
Pharmacoeconomics; 1998 May; 13(5 Pt 2):623-43. PubMed ID: 17165328
[TBL] [Abstract][Full Text] [Related]
7. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin Survival Study Group.
Johannesson M; Jönsson B; Kjekshus J; Olsson AG; Pedersen TR; Wedel H
N Engl J Med; 1997 Jan; 336(5):332-6. PubMed ID: 9011785
[TBL] [Abstract][Full Text] [Related]
8. Economic analysis of treatments reducing coronary heart disease mortality in England and Wales, 2000-2010.
Fidan D; Unal B; Critchley J; Capewell S
QJM; 2007 May; 100(5):277-89. PubMed ID: 17449875
[TBL] [Abstract][Full Text] [Related]
9. Costs and cost effectiveness of health checks conducted by nurses in primary care: the Oxcheck study.
Langham S; Thorogood M; Normand C; Muir J; Jones L; Fowler G
BMJ; 1996 May; 312(7041):1265-8. PubMed ID: 8634616
[TBL] [Abstract][Full Text] [Related]
10. The West of Scotland coronary prevention study: economic benefit analysis of primary prevention with pravastatin.
Caro J; Klittich W; McGuire A; Ford I; Norrie J; Pettitt D; McMurray J; Shepherd J
BMJ; 1997 Dec; 315(7122):1577-82. PubMed ID: 9437275
[TBL] [Abstract][Full Text] [Related]
11. At what coronary risk level is it cost-effective to initiate cholesterol lowering drug treatment in primary prevention?
Johannesson M
Eur Heart J; 2001 Jun; 22(11):919-25. PubMed ID: 11428815
[TBL] [Abstract][Full Text] [Related]
12. Cost effectiveness analysis of different approaches of screening for familial hypercholesterolaemia.
Marks D; Wonderling D; Thorogood M; Lambert H; Humphries SE; Neil HA
BMJ; 2002 Jun; 324(7349):1303. PubMed ID: 12039822
[TBL] [Abstract][Full Text] [Related]
13. Economic evaluation of cholesterol-related interventions in general practice. An appraisal of the evidence.
van der Weijden T; Knottnerus JA; Ament AJ; Stoffers HE; Grol RP
J Epidemiol Community Health; 1998 Sep; 52(9):586-94. PubMed ID: 10320860
[TBL] [Abstract][Full Text] [Related]
14. Pravastatin. A pharmacoeconomic review of its use in primary and secondary prevention of coronary heart disease.
Coukell AJ; Wilde MI
Pharmacoeconomics; 1998 Aug; 14(2):217-36. PubMed ID: 10186462
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis B vaccination: the cost effectiveness of alternative strategies in England and Wales.
Mangtani P; Hall AJ; Normand CE
J Epidemiol Community Health; 1995 Jun; 49(3):238-44. PubMed ID: 7629457
[TBL] [Abstract][Full Text] [Related]
16. Cost effectiveness of nurse led secondary prevention clinics for coronary heart disease in primary care: follow up of a randomised controlled trial.
Raftery JP; Yao GL; Murchie P; Campbell NC; Ritchie LD
BMJ; 2005 Mar; 330(7493):707. PubMed ID: 15716289
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of dietary treatment of hypercholesterolemia in Spain.
Rubió PP
Public Health; 1997 Jan; 111(1):33-40. PubMed ID: 9033222
[TBL] [Abstract][Full Text] [Related]
18. The cost-effectiveness of HMG-CoA reductase inhibitors to prevent coronary heart disease. Estimating the benefits of increasing HDL-C.
Hamilton VH; Racicot FE; Zowall H; Coupal L; Grover SA
JAMA; 1995 Apr; 273(13):1032-8. PubMed ID: 7897787
[TBL] [Abstract][Full Text] [Related]
19. Comparing costs and benefits over a 10 year period of strategies for familial hypercholesterolaemia screening.
Marks D; Thorogood M; Neil HA; Wonderling D; Humphries SE
J Public Health Med; 2003 Mar; 25(1):47-52. PubMed ID: 12669918
[TBL] [Abstract][Full Text] [Related]
20. Cost effectiveness of shortening screening interval or extending age range of NHS breast screening programme: computer simulation study.
Boer R; de Koning H; Threlfall A; Warmerdam P; Street A; Friedman E; Woodman C
BMJ; 1998 Aug; 317(7155):376-9. PubMed ID: 9694752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
